OVID ▲ +1.3% - Ovid Therapeutics Inc. $OVID some vol ah OVID As previously reported, Guggenheim initiated coverage of Ovid Therapeutics with a Buy rating and $7 price target. OV329, the company's lead asset, is a next-generation GABA-AT inhibitor engineered to preserve vigabatrin's clinically and commercially validated efficacy, while eliminating the retinal toxicity, says the analyst, who argues that this give Ovid "a rare setup in clinical-stage neuroscience" with a validated mechanism of action in epilepsy whose only approved drug is "crippled by irreversible eye toxicity, a lead asset built to beat it on exactly that axis." 05-OCT-2026 04:19 PM ET